3 transcripts
ALKS
Earnings call transcript
NASDAQ
2024 Q2
24 Jul 24
Phase II study, VIBRANCE1, which is a randomized placebo-controlled multinational study, evaluating the safety, tolerability and efficacy of 3
ALKS
Earnings call transcript
NASDAQ
2024 Q1
1 May 24
characterize the safety and efficacy profile of ALKS 2680, utilizing well-established efficacy endpoints, including the maintenance of wakefulness test
ALKS
Earnings call transcript
NASDAQ
2023 Q4
15 Feb 24
, lipid and glycemic parameters and a safety profile that was consistent with what we had seen in previous studies. The data highlight the potential
- Prev
- 1
- Next